The bipolar patient with comorbid substance use disorder: Recognition and management

CNS Drugs

Volumn 18, Issue 9, 2004, Pages 585-596

  Albanese, Mark J ^a,b   Pies, Ronald ^b,c  

^a CAMBRIDGE HEALTH ALLIANCE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CANNABIS; CLOZAPINE; COCAINE; DISULFIRAM; LAMOTRIGINE; LICARBAZEPINE; LITHIUM; METHADONE; NEUROLEPTIC AGENT; OPIATE; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROATE SEMISODIUM;

BIPOLAR DISORDER; CLINICAL TRIAL; COMORBIDITY; DATA BASE; HUMAN; MOOD DISORDER; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SIDE EFFECT; SOCIAL PSYCHOLOGY; SUBSTANCE ABUSE;

ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COMBINED MODALITY THERAPY; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; PSYCHOTHERAPY; SUBSTANCE-RELATED DISORDERS;

EID: 3242719321     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418090-00004     Document Type: Review

References (99)

1. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press Inc, 1990
2. Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a reexamination. Am J Psychiatry 2000 Dec; 157 (12): 1925-32
3. Inskip HM, Harris EC, Barraclough B. Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br J Psychiatry 1998 Jan; 172: 35-7
4. O'Leary D, Paykel E, Todd C, et al. Suicide in primary affective disorders revisited: a systematic review by treatment era. J Clin Psychiatry 2001 Oct; 62 (10): 804-11
5. Kleinman L, Lowin A, Flood E, et al. Costs of bipolar disorder. Pharmacoeconomics 2003; 21 (9): 601-22
6. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness: 1991. Soc Psychiatry Psychiatr Epidemiol 1995 Aug; 30 (5): 213-9
7. US Department of Health Education and Welfare. Medical practice project: a state of the science report for the office of the Assistant Secretary for the US Department of Health Education and Welfare. Baltimore (MD): 1979
8. Goldberg JF, Keck PE. Summary of findings on the course and outcome of bipolar disorders. In: Goldberg JF, Harrow M, editors. Bipolar disorders: clinical course and outcome. Washington, DC: American Psychiatric Press Inc, 1999: 275-88
9. Dunner DL, Fleiss JL, Fieve RR. Lithium carbonate prophylaxis failure. Br J Psychiatry 1976 Jul; 129: 40-4
10. Himmelhoch JM, Mulla D, Neil JF, et al. Incidence and signficiance of mixed affective states in a bipolar population. Arch Gen Psychiatry 1976 Sep; 33 (9): 1062-6
11. Keller MB, Lavori PW, Coryell W, et al. Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness. JAMA 1986 Jun; 255 (22): 3138-42
12. Post RM, Altshuler LL, Ketter TA, et al. Antiepileptic drugs in affective illness: clinical and theoretical implications. Adv Neurol 1991; 55: 239-77
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Publishing Inc, 1994
14. Brady K, Casto S, Lydiard RB, et al. Substance abuse in an inpatient psychiatric sample. Am J Drug Alcohol Abuse 1991; 17 (4): 389-97
15. Reich LH, Davies RK, Himmelhoch JM. Excessive alcohol use in manic-depressive illness. Am J Psychiatry 1974 Jan; 131 (1): 83-6
16. Sonne SC, Brady KT, Morton WA. Substance abuse and bipolar affective disorder. J Nerv Ment Dis 1994 Jun; 182 (6): 349-52
17. Young LT, Cooke RG, Robb JC, et al. Anxious and non-anxious bipolar disorder. J Affect Disord 1993 Sep; 29 (1): 49-52
18. Strakowski SM, Keck Jr PE, McElroy SL, et al. Twelve-month outcome after a first hospitalization for affective psychosis. Arch Gen Psychiatry 1998 Jan; 55 (1): 49-55
19. McLellan AT, Luborsky L, Woody GE, et al. Predicting response to alcohol and drug abuse treatments: role of psychiatric severity. Arch Gen Psychiatry 1983 Jun; 40 (6): 620-5
20. Albanese MJ, Khantzian EJ. The difficult-to-treat patient with substance abuse. In: Dewan MJ, Pies RW, editors. The difficult-to-treat psychiatric patient. Washington, DC: American Psychiatric Press, 2001: 273-98
21. O'Brien G. Dual diagnosis in offenders with intellectual disability: setting research priorities: a review of research findings concerning psychiatric disorder (excluding personality disorder) among offenders with intellectual disability. J Intellect Disabil Res 2002 May; 46 Suppl. 1: 21-30
22. Hien D, Zimberg S, Weisman S, et al. Dual diagnosis subtypes in urban substance abuse and mental health clinics. Psychiatr Serv 1997 Aug; 48 (8): 1058-63
23. Zimberg S. A dual diagnosis typology to improve diagnosis and treatment of dual disorder patients. J Psychoactive Drugs 1999 Jan; 31 (1): 47-51
24. Albanese MJ, Blair W, DiRocco D, et al. Depression as a predictor of compliance with substance abuse treatment [abstract]. Fifth Annual Research Day, The Consolidated Department of Psychiatry, Harvard Medical School; 1997 March 12; Boston (MA)
25. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994 Jan; 51 (1): 8-19
26. Brown ES, Suppes T, Adinoff B, et al. Drug abuse and bipolar disorder: comorbidity or misdiagnosis? J Affect Disord 2001 Jul; 65 (2): 105-15
27. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990 Nov; 264 (19): 2511-8
28. Heizer JE, Pryzbeck TR. The co-occurrence of alcoholism with other psychiatric disorders in the general population and its impact on treatment. J Stud Alcohol 1988 May; 49 (3): 219-24
29. Winokur G, Coryell W, Akiskal HS, et al. Alcoholism in manic-depressive (bipolar) illness: familial illness, course of illness, and the primary-secondary distinction. Am J Psychiatry 1995 Mar; 152 (3): 365-72
30. Winokur G. Alcoholism in bipolar disorder. In: Goldberg JF, Harrow M, editors. Bipolar disorders: clinical course and outcome. Washington, DC: American Psychiatric Press, 1999: 185-97
31. Berglund M. Suicide in alcoholism: a prospective study of 88 suicides: I. the multidimensional diagnosis at first admission. Arch Gen Psychiatry 1984 Sep; 41 (9): 888-91
32. Rich CL, Ricketts JE, Fowler RC, et al. Some differences between men and women who commit suicide. Am J Psychiatry 1988 Jun; 145 (6): 718-22
33. Tondo L, Baldessarini RJ, Hennen J, et al. Suicide attempts in major affective disorder patients with comorbid substance use disorders. J Clin Psychiatry 1999; 60 Suppl. 2: 63-9
34. Fawcett J. Predictors of early suicide: identification and appropriate intervention. J Clin Psychiatry 1988 Oct; 49 Suppl. 7-8: 7-8
35. Feinman JA, Dunner DL. The effect of alcohol and substance abuse on the course of bipolar affective disorder. J Affect Disord 1996 Feb; 37 (1): 43-9
36. McNiel DE. Correlates of violence in psychotic patients. Psychiatr Ann 1997; 27: 683-90
37. Pihl RO, Hoaken PNS. Clinical correlates and predictors of violence in patients with substance use disorders. Psychiatr Ann 1997; 27: 735-40
38. Swanson JW, Holzer III CE, Ganju VK, et al. Violence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment Area surveys. Hosp Community Psychiatry 1990 Jul; 41 (7): 761-70
39. Swanson JW. Mental disorder, substance abuse, and community violence: an epidemiologic approach. In: Monahan J, Steadman HJ, editors. Violence and mental disorders: developments in risk assessment. Chicago (IL): University of Chicago Press, 1994: 101-36
40. Swanson JW, Borum R, Swartz MS, et al. Psychotic symptoms and disorders and the risk of violence in the community. Crim Behav Ment Health 1996; 6: 309-29
41. Winokur G, Cook B, Liskow B, et al. Alcoholism in manic depressive (bipolar) patients. J Stud Alcohol 1993; 54: 574-6
42. Pies R. The "softer" end of the bipolar spectrum. J Psychiatr Pract 2002; 8 (4): 189-95
43. Cassidy F, Forest K, Murry E, et al. A factor analysis of the signs and symptoms of mania. Arch Gen Psychiatry 1998 Jan; 55 (1): 27-32
44. Ghaemi SN, Sachs GS, Chiou AM, et al. Differential diagnosis of bipolar disorder and the use of antidepressants: is bipolar underdiagnosed?: are antidepressants overutilized? [abstract]. American College of Neuropharmacology Annual Meeting; 1996 Dec 9-13; San Juan, Puerto Rico
45. Akiskal HS. The bipolar spectrum: new concepts in classification and diagnosis. In: Grinspoon L, editor. Psychiatry update: the American Psychiatric Association annual review. Washington, DC: American Psychiatric Press, 1983
46. Akiskal HS. The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV. J Clin Psychopharmacol 1996 Apr; 16 (2 Suppl. 1): 4S-14S
47. Akiskal HS, Mallya G. Criteria for the "soft" bipolar spectrum: treatment implications. Psychopharmacol Bull 1987; 23 (1): 68-73
48. McElroy SL, Strakowski SM, Keck Jr PE, et al. Differences and similarities in mixed and pure mania. Compr Psychiatry 1995 May; 36 (3): 187-94
49. Brady KT, Sonne SC. The relationship between substance abuse and bipolar disorder. J Clin Psychiatry 1995; 56 Suppl. 3: 19-24
50. Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: The Mood Disorder Questionnaire. Am J Psychiatry 2000 Nov; 157 (11): 1873-5
51. Miller CJ, Ghaemi SN, Klugman J, et al. Utility of mood disorder questionnaire and bipolar spectrum diagnostic scale. American Psychiatric Association 2002 Annual Meeting-Abstracts on Disk [CD ROM]. Washington, DC: American Psychiatric Association, 2002 May 18-23
52. Hasin DS, Trautman KD, Miele GM, et al. Psychiatric research interview for substance and mental disorders (PRISM): reliability for substance abusers. Am J Psychiatry 1996 Sep; 153 (9): 1195-201
53. Shaner A, Khalsa ME, Roberts L, et al. Unrecognized cocaine use among schizophrenic patients. Am J Psychiatry 1993 May; 150 (5): 758-62
54. Stone AM, Greenstein RA, Gamble G, et al. Cocaine use by schizophrenic outpatients who receive depot neuroleptic medication. Hosp Community Psychiatry 1993 Feb; 44 (2): 176-7
55. Weiss RD, Najavits LM, Greenfield SF, et al. Validity of substance use self-reports in dually diagnosed outpatients. Am J Psychiatry 1998 Jan; 155 (1): 127-8
56. Spitzer RL, Williams JB, Gibbon M, et al. Structured clinical interview for DSM-III-R, Patient Edition/Non-patient Edition (SCID-P/SCID-NP). 1990
57. Albanese MJ, Bartel RL, Bruno RF, et al. Comparison of measures used to determine substance abuse in an inpatient psychiatric population. Am J Psychiatry 1994 Jul; 151 (7): 1077-8
58. Kosten TR, Bryant K, Rounsaville BJ. The SCID: a clinical instrument for assessing psychiatric disorders. NIDA Res Monogr 1991; 105: 213-9
59. Breakey WR, Calabrese L, Rosenblatt A, et al. Detecting alcohol use disorders in the severely mentally ill. Community Ment Health J 1998 Apr; 34 (2): 165-74
60. Selzer ML, Vinokur A, van Rooijen L. A self-administered Short Michigan Alcoholism Screening Test (SMAST). J Stud Alcohol 1975 Jan; 36 (1): 117-26
61. Ewing JA. Detecting alcoholism: the CAGE questionnaire. JAMA 1984 Oct; 252 (14): 1905-7
62. Woody GE, McLellan AT, Luborsky L, et al. Severity of psychiatric symptoms as a predictor of benefits from psychotherapy: the Veterans Administration-Penn study. Am J Psychiatry 1984 Oct; 141 (10): 1172-7
63. McLellan AT, Luborsky L, Woody GE, et al. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis 1980 Jan; 168 (1): 26-33
64. Buckley PF. Substance abuse in schizophrenia: a review. J Clin Psychiatry 1998; 59 Suppl. 3: 26-30
65. Clodfelter RC, Albanese MJ, Baker G, et al. The MICA case conference program at Tewksbury Hospital, MA: an integrated treatment model. Am J Addict 2003; 12 (5): 448-54
66. Weiss RD, Greenfield SF, Najavits LM, et al. Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry 1998 Apr; 59 (4): 172-4
67. Albanese MJ. Safety and efficacy of risperidone in substance abusers with psychosis. Am J Addict 2001; 10 (2): 190-1
68. Albanese MJ, Clodfelter Jr RC, Khantzian EJ. Divalproex sodium in substance abusers with mood disorder. J Clin Psychiatry 2000 Dec; 61 (12): 916-21
69. Albanese MJ, Graham-Brown A, Vanelli M. Risperidone augmentation of clozapine [abstract]. Sixth Annual Research Day, The Consolidated Department of Psychiatry, Harvard Medical School; 1998 Apr 22; Boston (MA)
70. Geller B, Cooper TB, Sun K, et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry 1998 Feb; 37 (2): 171-8
71. Dorus W, Ostrow DG, Anton R, et al. Lithium treatment of depressed and nondepressed alcoholics. JAMA 1989 Sep; 262 (12): 1646-52
72. Nunes EV, McGrath PJ, Wager S, et al. Lithium treatment for cocaine abusers with bipolar spectrum disorders. Am J Psychiatry 1990 May; 147 (5): 655-7
73. Brady KT, Sonne SC, Anton R, et al. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry 1995 Mar; 56 (3): 118-21
74. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994 Mar; 271 (12): 918-24
75. Keck Jr PE, McElroy SL. Outcome in the pharmacologic treatment of bipolar disorder. J Clin Psychopharmacol 1996 Apr; 16 (2 Suppl. 1): 15S-23S
76. Goldberg JF, Garno JL, Leon AC, et al. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry 1999 Nov; 60 (11): 733-40
77. Hertzman M. Divalproex sodium to treat concomitant substance abuse and mood disorders. J Subst Abuse Treat 2000 Jun; 18 (4): 371-2
78. Tondo L, Baldessarini RJ. Reduced suicide risk during lithium maintenance treatment. J Clin Psychiatry 2000; 61 Suppl. 9: 97-104
79. Kallner G, Lindelius R, Petterson U, et al. Mortality in 497 patients with affective disorders attending a lithium clinic or after having left it. Pharmacopsychiatry 2000 Jan; 33 (1): 8-13
80. Calabrese JR, Shelton MD, Bowden CL, et al. Bipolar rapid cycling: focus on depression as its hallmark. J Clin Psychiatry 2001; 62 Suppl. 14: 34-41
81. Brady KT, Dansky BS, Sonne SC, et al. Posttraumatic stress disorder and cocaine dependence: order of onset. Am J Addict 1998; 7 (2): 128-35
82. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999 Feb; 60 (2): 79-88
83. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000 Nov; 61 (11): 841-50
84. Ballasiotes AA, Skaer TL. Use of lamotrigine in a patient with bipolar disorder and psychiatric comorbidity. Clin Ther 2000 Sep; 22 (9): 1146-8
85. Brown ES, Nejtek VA, Perantie DC, et al. Lamotrigine in patients with bipolar disorder and cocaine dependence. J Clin Psychiatry 2003 Feb; 64 (2): 197-201
86. Chengappa KN, Gershon S, Levine J. The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disord 2001 Oct; 3 (5): 215-32
87. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003 May; 361 (9370): 1677-85
88. Brown ES, Thomas NR, Carmody T, et al. Atypical antipsychotics in bipolar and schizoaffective disorders. Pharmacopsychiatry 2001 Mar; 34 (2): 80-1
89. Albanese MJ, Khantzian EJ, Murphy SL, et al. Decreased substance use in chronically psychotic patients treated with clozapine. Am J Psychiatry 1994 May; 151 (5): 780-1
90. Drake RE, Xie H, McHugo GJ, et al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000; 26 (2): 441-9
91. Albanese MJ. Risperidone in substance abusers with bipolar disorder [abstract]. American College of Neuropsychopharmacology 39th Annual Meeting; 2000 Dec 10-14; San Juan, Puerto Rico
92. Brown ES, Nejtek VA, Perantie DC, et al. Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord 2002; 4 (6): 406-11
93. Weiss RD, Najavits LM, Greenfield SF. A relapse prevention group for patients with bipolar disorder and substance use disorders. J Subst Abuse Treat 1999; 16: 47-54
94. Rothbaum BO, Astin MC. Integration of pharmacotherapy and psychotherapy for bipolar disorder. J Clin Psychiatry 2000; 61 Suppl. 9: 68-75
95. Schmitz JM, Averill P, Sayre S, et al. Cognitive-behavioral treatment of bipolar disorder and substance abuse: a preliminary randomized study. Addict Disord Treat 2002; 1 (1): 17-24
96. Weiss RD, Griffin ML, Greenfield SF, et al. Group therapy for patients with bipolar disorder and substance dependence: results of a pilot study. J Clin Psychiatry 2000 May; 61 (5): 361-7
97. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the addiction severity index. J Subst Abuse Treat 1992; 9 (3): 199-213
98. Drake RE, Mercer-McFadden C, Mueser KT, et al. Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophr Bull 1998; 24 (4): 589-608
99. US Department of Health and Human Services, SAMHSA. Report to congress on the prevention and treatment of co-occurring substance abuse disorders and mental disorders. Nov 2002: 75